Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®

NCT06375343 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease
Dry Eye Sensation
Ocular Surface Disease

Interventions

DRUG: PRO-240
DRUG: Optive®

Sponsor

Laboratorios Sophia S.A de C.V.